Drug Profile
Arundic acid - Ono Pharmaceutical
Alternative Names: Arocyte Injection; Cereact Capsule; MK-0724; ONO-2506; ONO-2506PO; Proglia®Latest Information Update: 18 Mar 2010
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Developer Merck & Co; Ono Pharmaceutical
- Class Neuroprotectants; Nootropics; Octanoic acids; Small molecules
- Mechanism of Action Astrocyte modulators; Cyclo-oxygenase 2 inhibitors; Free radical scavengers; Nitric oxide synthase type II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease; Stroke
Most Recent Events
- 01 Nov 2006 This compound is still in active development for Alzheimer's disease in Japan
- 01 Nov 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the Alzheimer's disease pharmacodynamics section
- 18 Aug 2006 Commencement of phase-II clinical trials in Stroke planned in North America (IV)